Applied Therapeutics
APLT

$7.77

2.88%

Market Cap: $892M

About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Employees: 31

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1,040% more call options, than puts

Call options by funds: $4.97M | Put options by funds: $436K

30% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 23

16% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 25

4% more funds holding

Funds holding: 89 [Q1] → 93 (+4) [Q2]

0.87% less ownership

Funds ownership: 91.76% [Q1] → 90.89% (-0.87%) [Q2]

27% less capital invested

Capital invested by funds: $660M [Q1] → $484M (-$176M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

3%

upside

Avg. target

$11.25

45%

upside

High target

$14

80%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Citigroup Yigal Nochomovitz 48% 1-year accuracy 21 / 44 met price target	42%upside $11	Buy Maintained	19 Sept 2024
Leerink Partners Joseph Schwartz 40% 1-year accuracy 2 / 5 met price target	80%upside $14	Outperform Maintained	19 Sept 2024
Citigroup Yigal Nochomovitz 48% 1-year accuracy 21 / 44 met price target	3%upside $8	Buy Maintained	27 Aug 2024
RBC Capital Brian Abrahams 51% 1-year accuracy 40 / 78 met price target	54%upside $12	Outperform Reiterated	17 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about APLT published over the past 30 days

Zacks Investment Research

APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA

Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.

APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer

Applied Therapeutics, Inc.'s stock surged nearly 70% yesterday after the news that the FDA will not hold an AdCom to discuss approval of AT-007 in galactosemia. AT-007 has shown clinical benefits in galactosemia and SORD deficiency, and its PDUFA for the former arrives at the end of November. With no AdCom, approval seems the likeliest outcome. Despite financial constraints, strong patient and HCP support suggest a successful commercial launch for govorestat, making Applied stock a “Buy” with expected valuation growth.

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

FDA removes the need for an advisory panel to first give a recommendation review of Applied Therapeutics, Inc.'s govorestat for the treatment of patients with galactosemia. PDUFA date of November 28th, 2024, remains on track for the FDA to decide whether govorestat should be approved to treat patients with galactosemia. Pre-NDA meeting with FDA expected in 2nd half of 2024 to discuss possible administrative actions of NDA filing submission of govorestat for the treatment of patients with SORD deficiency.

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

The Motley Fool

Why Applied Therapeutics Stock Is Skyrocketing Today

The FDA won't hold an Advisory Committee meeting to review Applied Therapeutics' regulatory filing for govorestat. This move could increase the likelihood that the drug will win FDA approval.

Why Applied Therapeutics Stock Is Skyrocketing Today

Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside

William Blair initiated coverage on Applied Therapeutics Inc. APLT, a late-stage development company focused on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy.

Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside

Applied Therapeutics Added to Russell 3000® Index

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was added to the Russell 3000® Index, effective after the U.S. market closed on June 28, 2024, as part of the 2024 Russell indexes annual reconstitution.

Applied Therapeutics Added to Russell 3000® Index

Top 4 Health Care Stocks That May Keep You Up At Night This Month

As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 4 Health Care Stocks That May Keep You Up At Night This Month

Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia

Applied Therapeutics is a clinical-stage biotech focused on treating symptoms of galactosemia in the central nervous system. Govorestat (AT-007) is in late-stage regulatory approval for galactosemia, with a PDUFA date set for November 2024. APLT holds $146.5 million in cash, ensuring a sufficient runway to FDA approval and initial product revenues by early 2025.

Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia

Applied Therapeutics Reports First Quarter 2024 Financial Results

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2024.

Applied Therapeutics Reports First Quarter 2024 Financial Results

Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately. Mr. Hooks joins Applied with over 30 years of biopharmaceutical experience in rare disease marketing and sales, holding various leadership roles. Mr. Hooks will be responsible for leading Applied's commercial preparations for the potential launch of govorestat for the treatment of Classic Galactosemia and SORD.

Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

See News Rankings